Who are MYL-1601D Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ertugliflozin 15 mg, Comparator monotherapy empagliflozin, Empagliflozin + Carvedilol, Ertugliflozin 5 mg, NBF, Dapagliflozin (DAPA).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/myl-1601d-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MYL-1601D Product — Competitive Intelligence Brief

MYL-1601D Product (MYL-1601D Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

phase 3 SGLT2 inhibitor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

MYL-1601D Product (MYL-1601D Product) — Mylan Inc.. MYL-1601D Product is a generic version of a medication that helps to lower blood sugar levels in people with type 2 diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MYL-1601D Product TARGET	MYL-1601D Product	Mylan Inc.	phase 3	SGLT2 inhibitor
Ertugliflozin 15 mg	ertugliflozin-15-mg	Pfizer	marketed	SGLT2 inhibitor	SGLT2
Comparator monotherapy empagliflozin	Comparator monotherapy empagliflozin	The George Institute	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Empagliflozin + Carvedilol	Empagliflozin + Carvedilol	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	SGLT2 inhibitor + non-selective beta-blocker combination	SGLT2 and beta-adrenergic receptors (β1, β2, α1)
Ertugliflozin 5 mg	ertugliflozin-5-mg	Pfizer	marketed	SGLT2 inhibitor	SGLT2
NBF	NBF	Universidad Complutense de Madrid	marketed	SGLT2 inhibitor	SGLT2
Dapagliflozin (DAPA)	Dapagliflozin (DAPA)	Ottawa Heart Institute Research Corporation	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MYL-1601D Product — Competitive Intelligence Brief. https://druglandscape.com/ci/myl-1601d-product. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab